Pharmaceutical Benefits Scheme Change For Crohn’s Disease
A change to the Pharmaceutical Benefits Scheme (PBS) from 1 October 2007 will provide subsidised access to adults and children of Remicade® (infliximab) for the treatment of Crohn’s disease.Crohn’s disease is an inflammatory disorder of the gastrointestinal tract. It can have a profound impact on professional, family and social life. Those with active Crohn’s disease experience chronic abdominal pain, diarrhoea and bowel movements containing blood.
